Tomoko Maeda-Chubachi, MD, PhD, MBA, is a physician-scientist and regulatory strategist with extensive experience in dermatology and immunology drug development. She has held leadership roles across biotech and pharmaceutical companies including Pelthos Therapeutics, Novan, Eli Lilly, GSK, and Pfizer.
Most recently, she led the NDA and U.S. approval of berdazimer gel (Zelsuvmi) for molluscum contagiosum. Her work has also contributed to the development of therapies including VTAMA®, Taltz®, and Xeljanz®. Dr. Maeda-Chubachi also leads TMC Clinical Development Consulting, advising companies on global clinical and regulatory strategy.